Pens for the diabetes drug Ozempic sit on the manufacturing line being packaged at Danish pharmaceutical firm Novo Nordisk’s facility in Hillerød, Denmark. File | Photograph credit score: Reuters
Indian drugmakers Solar Pharmaceutical Industries, Zydus Lifesciences and Alkem Laboratories have obtained regulatory approval to fabricate and promote generic variations of blockbuster weight reduction and diabetes medicine Wigovy and Ozempic.
Final week, Zydus Lifesciences and Alkem Laboratories obtained approval to fabricate and market generic semaglutide for weight reduction and diabetes remedy, based on information on the regulator’s web site.
The businesses, which haven’t but introduced approval, didn’t instantly reply. Reuters Information Company Request a remark.
Solar Pharma, India’s largest pharmaceutical firm by gross sales, introduced on Friday (January 23) that it has obtained approval to launch generic medicine below the model names Nobeltreat for weight problems and Sematrinity for diabetes.
The patent for Danish pharmaceutical firm Novo Nordisk’s Wigovy and semaglutide, the lively ingredient in its diabetes drug Ozempic, is scheduled to run out in March 2026.
The upcoming patent expiration of semaglutide opens the door for generic drug makers on this nation to enter the burden loss market with cheaper variations of each Wegovy and Ozempic at deep reductions.
Final 12 months, US drugmaker Eli Lilly launched Mounjaro in India, and Novo launched Wegovy and Ozempic. Gross sales of modern medicines doubled instantly after their launch.
The worldwide weight reduction drug market is projected to succeed in $150 billion by the top of 2010.
Ozempic is primarily accepted for sort 2 diabetes, however it is usually used off-label for weight reduction due to its urge for food suppressant results.
Earlier this week, Dr. Reddy’s Laboratories introduced that it had obtained approval to promote a generic model of Ozempic.
“Generic firms will are available in at decrease costs and broaden the variety of folks they’ll attain given their aggressive advertising and marketing methods,” stated Vishal Manchanda, an analyst at Systematics Institutional Equities, including that there are a minimum of a dozen different generic firms awaiting approval.
